Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: A scoping review
Research output: Contribution to journal › Review › Research › peer-review
Standard
Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity : A scoping review. / Baden, Christoffer S.; Andersen, Jon T.; Christensen, Mikkel B.; Gade, Christina.
In: Adverse Drug Reaction Bulletin, Vol. 339, No. 1, 2023, p. 1315-1318.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity
T2 - A scoping review
AU - Baden, Christoffer S.
AU - Andersen, Jon T.
AU - Christensen, Mikkel B.
AU - Gade, Christina
N1 - Publisher Copyright: © 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023
Y1 - 2023
N2 - As obesity continues to be a global health challenge presenting various negative impacts on health outcomes and healthcare costs, there is a growing need for pharmacological interventions to address the issue. Glucagon-like peptide-1 receptor agonists have shown potential in treating obesity and reducing the risk of type 2 diabetes, but there is a lack of studies comparing adverse events across different populations. This review intends to indirectly compare the adverse events of available glucagon-like peptide-1 receptor agonist pharmaceuticals for treating overweight or obesity in adults, adolescents, and children.
AB - As obesity continues to be a global health challenge presenting various negative impacts on health outcomes and healthcare costs, there is a growing need for pharmacological interventions to address the issue. Glucagon-like peptide-1 receptor agonists have shown potential in treating obesity and reducing the risk of type 2 diabetes, but there is a lack of studies comparing adverse events across different populations. This review intends to indirectly compare the adverse events of available glucagon-like peptide-1 receptor agonist pharmaceuticals for treating overweight or obesity in adults, adolescents, and children.
U2 - 10.1097/FAD.0000000000000067
DO - 10.1097/FAD.0000000000000067
M3 - Review
AN - SCOPUS:85151815843
VL - 339
SP - 1315
EP - 1318
JO - Adverse Drug Reaction Bulletin
JF - Adverse Drug Reaction Bulletin
SN - 0044-6394
IS - 1
ER -
ID: 344447603